I usually never invest in biotech stocks, however this is an exception since i find the R/R and the odds of them actually nailing the phase-3 results incredibly big.
KPI and Short summary is:
\- Readout the end of May
\- Failed in 2022 by 3%, has since remade the formula and has in clinical trials improved their result with about 20 (!!!)%
\- Last time the mcap was around 250sek, now 200msek BUT this time they already have a agreeement with Menarini Relife who will produce it, launch it in about 150 countries, sell it and fix everything so the product will hit market in 2026
\- Its a patented way of applying/using existing pharmas, so that lowers the risk by a lot.
I´ll share with you a short DD, its listed on the Stockholm Exchange, and if its not obvious - I am invested. But honestly I think the odds of presenting a positive result is above 90% and the stock should, at the very least 2-3x from the current price.
Sharing a short dd i´ve made and tried to translate for you guys to the best of my ability.
Good luck, have fun my ballsy friends.